Statistics from Altmetric.com
Can buprenorphine implants effectively treat opioid dependence?
163 adults (aged 18–65) with current DSM-IV opioid dependence. Exclusions: AIDS, current dependence on psychoactive substances other than opioids or nicotine, current pain diagnosis that required opioid treatment, current use of non-prescribed benzodiazepines or receipt of medication treatment for opioid dependence in the past 90 days.
Six academic, three Veterans Affairs and nine non-profit community addiction treatment centres, USA; April 2007 to June 2008.
Subdermal buprenorphine or placebo implants for 6 months (four implants used, each buprenorphine implant 80 mg). Prior to randomisation all participants received sublingual buprenorphine–naloxone induction for at least 3 consecutive days. Additional supervised use of sublingual buprenorphine–naloxone tablets was permitted in both groups if withdrawal symptoms necessitated intervention. All participants received individual drug counselling: two sessions per week during weeks 1–12, then weekly thereafter. Failure to attend six consecutive sessions resulted in withdrawal from the study.
Primary: percentage of urine samples negative for illicit opioids for each participant during weeks …
Source of funding Titan Pharmaceuticals.
Competing interests DF has received honoraria for serving on an external advisory board designed to monitor diversion and abuse of buprenorphine.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.